Baseline demographics and disease characteristics
| . | All treated patients, N = 91 . |
|---|---|
| Median age (range), y | 34 (18, 69) |
| Sex, n (%) | |
| Male | 40 (44) |
| Female | 51 (56) |
| Disease stage at initial diagnosis, n (%) | |
| I | 1 (1) |
| II | 52 (57) |
| III | 16 (18) |
| IV | 20 (22) |
| Unknown | 2 (2) |
| Prior systemic therapy regimens,* n (%) | |
| ABVD | 82 (90) |
| BEACOPP | 2 (2) |
| Radiation | 18 (20) |
| Stanford V | 3 (3) |
| Other | 8 (9) |
| Best response to prior line of therapy, n (%) | |
| CR | 52 (57) |
| PR | 11 (12) |
| SD | 3 (3) |
| PD | 24 (26) |
| Unknown | 1 (1) |
| No. of prior therapies, including radiation | |
| Mean (STD) | 1.2 (0.5) |
| Median | 1.0 |
| Minimum, maximum | 1, 3 |
| Disease status relative to frontline treatment, n (%) | |
| Primary refractory | 38 (42) |
| PR or SD to frontline therapy | 13 (14) |
| PD to frontline therapy | 24 (26) |
| Unknown response to frontline therapy | 1 (1) |
| Relapsed, remission duration ≤1 y | 27 (30) |
| Relapsed, remission duration >1 y | 26 (29) |
| ECOG performance status, n (%) | |
| Grade 0 | 58 (64) |
| Grade 1 | 32 (35) |
| Bulky disease at baseline, n (%) | 12 (13) |
| Extranodal disease at baseline, n (%) | 24 (26) |
| . | All treated patients, N = 91 . |
|---|---|
| Median age (range), y | 34 (18, 69) |
| Sex, n (%) | |
| Male | 40 (44) |
| Female | 51 (56) |
| Disease stage at initial diagnosis, n (%) | |
| I | 1 (1) |
| II | 52 (57) |
| III | 16 (18) |
| IV | 20 (22) |
| Unknown | 2 (2) |
| Prior systemic therapy regimens,* n (%) | |
| ABVD | 82 (90) |
| BEACOPP | 2 (2) |
| Radiation | 18 (20) |
| Stanford V | 3 (3) |
| Other | 8 (9) |
| Best response to prior line of therapy, n (%) | |
| CR | 52 (57) |
| PR | 11 (12) |
| SD | 3 (3) |
| PD | 24 (26) |
| Unknown | 1 (1) |
| No. of prior therapies, including radiation | |
| Mean (STD) | 1.2 (0.5) |
| Median | 1.0 |
| Minimum, maximum | 1, 3 |
| Disease status relative to frontline treatment, n (%) | |
| Primary refractory | 38 (42) |
| PR or SD to frontline therapy | 13 (14) |
| PD to frontline therapy | 24 (26) |
| Unknown response to frontline therapy | 1 (1) |
| Relapsed, remission duration ≤1 y | 27 (30) |
| Relapsed, remission duration >1 y | 26 (29) |
| ECOG performance status, n (%) | |
| Grade 0 | 58 (64) |
| Grade 1 | 32 (35) |
| Bulky disease at baseline, n (%) | 12 (13) |
| Extranodal disease at baseline, n (%) | 24 (26) |
ABVD, adriamycin bleomycin vinblastine dacarbazine; BEACOPP, bleomycin etoposide adriamycin cyclophosphamide oncovin procarbazine prednisone; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; PR, partial response; SD, stable disease; STD, standard deviation
Patients may have received >1 therapy.